Why is SELLAS Life Sciences Group, Inc. (SLS) stock trending?
- The company's stock price was affected by a news event, with the stock price dropping significantly.
- There are concerns about potential lawsuits and the company's ability to maintain its stock price.
- The company's GPS program is still the lead program carrying it into ASH, and upcoming events include a database lock, secondary pricing details, and a topline data readout on SLS009.
| Attention | 30-day average attention | Change | |
|---|---|---|---|
| SLS | |||
| SLS | 3% | 0.94% | +2.06 pts |
Is SLS stock sentiment bullish or bearish?
| Bullish | Bearish | ||
|---|---|---|---|
| SLS | |||
| SLS | 63% | 37% | |
| SLS, 30-day average | |||
| SLS, 30-day average | 75% | 25% | |
| Healthcare sector | |||
| Healthcare sector | 62% | 38% | |
| All stocks | |||
What are investors saying about SLS stock?
We train models to sort every post about SELLAS Life Sciences Group, Inc. into topics, then summarize what each group is saying. Each bar is the share of the engagement on SLS posts that went to that topic.
| Share of engagement | 30-day average share | ||
|---|---|---|---|
| Technical Analysis chart patterns and price levels | |||
| Technical Analysis chart patterns and price levels | 5% | 3% | |
What does technical analysis say about SLS stock?
- The stock's price may be set at a significant discount to its current closing price, potentially in the mid to low teens, to attract institutional interest.
- The stock's volume has been increasing, with off-exchange volume running 3.1x normal, and the technicals are clear of its key averages, including the 50-day and 200-day averages.
What is the latest news on SLS stock?
- Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs
The vaccine reduced risk of death for certain acute myeloid leukemia patients, according to drugmaker
The Washington Post · 21h ago - Sellas Life Sciences stock falls on $150M stock offeringInvesting.com · 1d ago
- Sellas Life Sciences: REGAL Hits, But The Data Leaves Too Many Questions Unanswered
Analyst rates Sellas Life Sciences a Sell: its roughly $4 billion valuation outstrips GPS's roughly $826 million risk-adjusted U.S.
Seeking Alpha · 1d ago - 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · 1d ago
- Amer Sports, Sellas Life Sciences, Similarweb And Other Big Stocks Moving Higher On TuesdayBenzinga · 1d ago
Who is talking about SLS stock?
| Newcomers | Regulars | ||
|---|---|---|---|
| SLS | |||
| SLS | 26% | 74% | |
| SLS, 30-day average | |||
| SLS, 30-day average | 13% | 87% | |
| All stocks | |||
| All stocks | 43% | 57% | |
How does SLS compare with other Healthcare stocks?
We compare Healthcare stocks by attention, our measure of how much of the conversation each one gets. We add up the likes, replies and reposts on every post about Healthcare stocks on X, Reddit, Stocktwits and YouTube. A stock's attention is its share of that total. Each bar is that share.
| Share of Healthcare attention | ||
|---|---|---|
| SLS | ||
| SLS | 29% | |
| CAPR | ||
| CAPR | 7.9% | |
| AKAN | ||
| AKAN | 6% | |